Differential prognostic values of the three AKT isoforms in acute myeloid leukemia

• Published in: Scientific reports Vol. 14; no. 1; pp. 7070 - 12
• Main Authors: Corre, Eulalie, Soum, Cécile, Pfeifer, Romain, Bessière, Chloé, Dailhau, Sandra, Marbœuf, Catherine, Meggetto, Fabienne, Touriol, Christian, Récher, Christian, Bousquet, Marina, Pyronnet, Stéphane
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 25.03.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 1-Phosphatidylinositol 3-kinase; 631/67/1857; 631/67/1990; Acute myeloid leukemia; AKT protein; AKT1 protein; AKT2 protein; Biochemistry, Molecular Biology; Cancer; Cell differentiation; Genomics; Hematology; Hematopoietic stem cells; Human health and pathology; Humanities and Social Sciences; Isoforms; Leukemia; Leukocytes (granulocytic); Life Sciences; Monocytes; Monocytic leukemia; multidisciplinary; Mutation; Myelodysplastic syndrome; Runx1 protein; Science; Science (multidisciplinary); Stem cells; TOR protein; Translocation; Tumorigenesis
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-57578-x

The PI3K-AKT-mTOR pathway lies at the confluence of signaling pathways in which various components are subjected to activating genetic alterations in acute myeloid leukemia (AML), thus contributing to oncogenesis. Three AKT isoforms exist in humans. However, whether one isoform predominates in AML remains unknown. This study reveals that AKT3 behaves very distinctly than AKT1 or AKT2 in both normal myeloid differentiation and AML. During normal differentiation, AKT3 is preferentially expressed in hematopoietic stem cells whilst AKT1 becomes preferentially expressed as cells differentiate into granulocytes or monocytes. AKT2 expression remains unchanged. In AML, AKT3 expression varies widely among patient samples and is counterintuitively high in mature/monocytic leukemia. Furthermore, a low level of AKT3 expression is strongly correlated to genetic alterations associated with a better outcome ( NPM1 mutations and RUNX1 - RUNX1T1 translocation), while a high level is correlated to alterations associated to a bad outcome ( RUNX1 mutations; and SRSF2 , U2AF1 , SF3B1 , ASXL1 and BCOR mutations occurring frequently in MDS and MPN). Consistently, a high AKT3 expression level appears as a very strong predictor of poor survival. Curiously, although modestly varying among AML samples, a high AKT1 expression shows in contrast as a strong predictor of a better patient outcome. These data suggest that AKT3 and AKT1 expressions have strong, yet opposite, prognostic values.